Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.

Phil McEwanRebecca BoyceJuan Jose Garcia SanchezC David SjöströmBergur StefanssonStephen NolanRicardo Correa-RotterEllen BurgessGlenn M ChertowJohn J V McMurrayDavid C WheelerHiddo J Lambers Heerspink

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022)

Adding dapagliflozin to standard therapeutic management of CKD is expected to have long-term cardiorenal benefit beyond what has been demonstrated in the DAPA-CKD trial, with patients predicted to live longer with fewer complications.

Keyphrases

chronic kidney disease
end stage renal disease
study protocol
clinical trial
phase iii
ejection fraction
phase ii
peritoneal dialysis
preterm infants
prognostic factors
randomized controlled trial
risk factors